aimmtherapeutics.com
Platform licensing | AIMM Therapeutics
http://www.aimmtherapeutics.com/partnering/licensing
CEO Jan de Vries. COO Willem van Oort. Platform licensing with tech transfer guidance. AIMM will license the use of its technology to companies interested in developing antibodies for research or diagnostic purposes. AIMM will support and facilitate the technology transfer process required to ensure successfully implementation of the platform. CEO Jan de Vries. COO Willem van Oort. MEDI8897 on fast track. MEDI8897 into Phase Ib/IIa. 10 year anniversary symposium. New CEO and VP.
aimmtherapeutics.com
ERC Advanced Grant | AIMM Therapeutics
http://www.aimmtherapeutics.com/news-and-events/2013/erc-advanced-grant
CEO Jan de Vries. COO Willem van Oort. Prestigious ERC Advanced Grant awarded to CSO Hergen Spits. August 13, 2013. AIMMs CSO Hergen Spits received a prestigious ERC Advanced Grant. From the European Research Council. Subscribe to our e-mail newsletter to receive updates. PNAS publication: characterization of group 2 Influenza antibodies. Nature SciBX reviews D25 guided RSV vaccine study. CEO Jan de Vries. COO Willem van Oort. MEDI8897 on fast track. MEDI8897 into Phase Ib/IIa. New CEO and VP.
aimmtherapeutics.com
PNAS publication: characterization of group 2 Influenza antibodies | AIMM Therapeutics
http://www.aimmtherapeutics.com/news-and-events/2013/pnas-publication
CEO Jan de Vries. COO Willem van Oort. PNAS publication: characterization of group 2 Influenza antibodies. PNAS publication: characterization of group 2 Influenza antibodies. PNAS publication: characterization of group 2 Influenza antibodies. December 11, 2013. Published in PNAS: 2014 Jan 7;111(1):445-50. A common solution to group 2 influenza virus neutralization. Subscribe to our e-mail newsletter to receive updates. Nature SciBX reviews D25 guided RSV vaccine study. CEO Jan de Vries. New CEO and VP.
aimmtherapeutics.com
Licensing antibodies | AIMM Therapeutics
http://www.aimmtherapeutics.com/partnering/therapeutic-licensing
CEO Jan de Vries. COO Willem van Oort. Licensing an antibody from the AIMM pipeline. AIMM has active internal discovery programs in oncology and infectious diseases. When selecting potential candidates, AIMM sets the bar high. All of AIMM’s portfolio antibodies are either best in class. Or first in class. Antibody candidates are preferably selected from immune cells of individuals with unique attributes for overcoming disease. The portfolio includes the following antibody programs. Hepatitis C virus (HCV).
aimmtherapeutics.com
2014 | AIMM Therapeutics
http://www.aimmtherapeutics.com/category/news-and-events/2014
CEO Jan de Vries. COO Willem van Oort. December 22, 2014. A Netherlands Cancer Institute (NKI) publication co-authored by AIMM Therapeutics in Nature Medicine reveals that recognition of neo-antigens by CD4 T cells is a common phenomenon in melanoma. December 11, 2014. A bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity. AIMM Therapeutics’ 10 year anniversary symposium. October 3, 2014. MedImmune Starts Clinical Studies with RSV Antibody. July 2, 2014.
aimmtherapeutics.com
News and events | AIMM Therapeutics
http://www.aimmtherapeutics.com/category/news-and-events
CEO Jan de Vries. COO Willem van Oort. Killer antibodies against AML, press conference EHA 2016. June 15, 2016. At a press conference at EHA 2016, details of our work about the discovery of antibodies that bind specifically to AML cells from patients who are in remission from AML was presented. MEDI8897 Receives Fast Track Designation. April 9, 2015. MEDI8897 Advances Into Phase Ib/IIa Study. March 9, 2015. December 22, 2014. December 11, 2014. AIMM Therapeutics’ 10 year anniversary symposium. MedImmune ...
aimmtherapeutics.com
Nature SciBX reviews D25 guided RSV vaccine study | AIMM Therapeutics
http://www.aimmtherapeutics.com/news-and-events/2013/nature-scibx-reviews-d25-guided-rsv-vaccine-study
CEO Jan de Vries. COO Willem van Oort. Nature SciBX reviews D25 guided RSV vaccine study. Nature SciBX reviews D25 guided RSV vaccine study. Nature SciBX reviews D25 guided RSV vaccine study. November 14, 2013. Science-Business eXchange published an article discussing the recent Science study that used AIMMs D25 anti RSV antibody for vaccine design. Click here. To read the paper. Subscribe to our e-mail newsletter to receive updates. PNAS publication: characterization of group 2 Influenza antibodies.
aimmtherapeutics.com
2012 | AIMM Therapeutics
http://www.aimmtherapeutics.com/category/news-and-events/2012
CEO Jan de Vries. COO Willem van Oort. Strategic partnership with Cosmo Pharmaceuticals. December 19, 2012. AIMM Therapeutics in strategic partnership with Cosmo Pharmaceuticals to combine Cosmo’s extended release technology and AIMM’s high quality antibodies to successfully combat gastrointestinal disease. New CEO and VP Business Development. November 8, 2012. AIMM Therapeutics appoints former head Novartis Research Institutes Jan de Vries CEO, and John Womelsdorf VP Business Development. June 15, 2012.
